Biophytis soared by over 26% on the Paris Bourse on Tuesday, after announcing the launch of a new clinical program in the treatment of obesity.

According to the biotech company, its lead drug candidate, BIO101, has the potential to become the reference molecule for preserving muscle function in obese patients treated with GLP-1 RA.

While glucagon-like peptide 1 receptor (GLP-1 RA) agonists - such as Novo Nordisk's Ozempic - are highly effective drugs for achieving significant weight loss, they are also likely to cause a loss of muscle mass and function.

Biophytis specifies that its Phase 2 clinical trial is due to start in mid-2024, following regulatory approval, with the first patients being treated in the second half of 2024.

The first efficacy results should be available in 2025.

According to Goldman Sachs, some 15 million adults in the United States should be treated with an anti-obesity drug by
2030, representing a market worth $100 billion.

Copyright (c) 2024 All rights reserved.